The specific NPY4R agonist, BA-129 inhibits the proliferation of pancreatic cancer cells in vitro [25], and genetic and structural variations in NPY4R have been implicated in the pathogenesis of obesity [26]. Here, NPY4R is linked to obesity disorder.